HC Wainwright Reiterates “Buy” Rating for BioNTech (NASDAQ:BNTX)
HC Wainwright restated their buy rating on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report published on Thursday, Benzinga reports. The firm currently has a $113.00 price objective on the stock. Several other research firms also recently commented on BNTX. BMO Capital Markets dropped their price objective on shares of BioNTech from $123.00 […]
More Stories
Theta Network 24 Hour Trading Volume Reaches $22.76 Million (THETA)
Theta Network (THETA) traded down 7% against the U.S. dollar during the 24-hour period ending at 15:00 PM E.T. on...
ONUS Reaches 24 Hour Volume of $1.64 Million (ONUS)
ONUS (ONUS) traded 0.9% higher against the dollar during the 24-hour period ending at 15:00 PM E.T. on October 10th....
Polymesh Trading 2% Lower Over Last 7 Days (POLYX)
Polymesh (POLYX) traded 6% lower against the U.S. dollar during the 1-day period ending at 15:00 PM E.T. on October...
XIDO FINANCE Self Reported Market Cap Tops $24.46 Million (XIDO)
XIDO FINANCE (XIDO) traded up 1.5% against the US dollar during the twenty-four hour period ending at 15:00 PM ET...
BitTorrent-New (BTT) Price Down 0.6% Over Last Week
BitTorrent-New (BTT) traded down 2.8% against the U.S. dollar during the one day period ending at 15:00 PM E.T. on...
Pharming Group (NASDAQ:PHAR) and AstraZeneca (NASDAQ:AZN) Critical Contrast
AstraZeneca (NASDAQ:AZN – Get Free Report) and Pharming Group (NASDAQ:PHAR – Get Free Report) are both medical companies, but which...